Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$11.90 USD
+0.66 (5.87%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.89 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Oric Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 208 | 206 | 237 | 294 | 89 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 4 | 3 | 1 |
Total Current Assets | 213 | 210 | 241 | 297 | 90 |
Net Property & Equipment | 3 | 3 | 2 | 2 | 2 |
Investments & Advances | 27 | 22 | 43 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 10 | 12 | 12 | 0 | 2 |
Total Assets | 252 | 247 | 299 | 299 | 94 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 14 | 13 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 15 | 15 | 9 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7 | 9 | 11 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 178 |
Total Liabilities | 28 | 25 | 26 | 9 | 184 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 659 | 558 | 518 | 456 | 3 |
Retained Earnings | -435 | -334 | -245 | -166 | -93 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 224 | 222 | 273 | 290 | -90 |
Total Liabilities & Shareholder's Equity | 252 | 247 | 299 | 299 | 94 |
Total Common Equity | 224 | 222 | 273 | 290 | -90 |
Shares Outstanding | 67.30 | 39.50 | 39.30 | 30.80 | NA |
Book Value Per Share | 3.33 | 5.63 | 6.95 | 9.41 | 0.00 |
Fiscal Year End for Oric Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 317 | 208 | 227 | 264 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 4 | 5 | 4 |
Total Current Assets | NA | 324 | 213 | 232 | 268 |
Net Property & Equipment | NA | 3 | 3 | 3 | 3 |
Investments & Advances | NA | 15 | 27 | 29 | 10 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 9 | 10 | 10 | 11 |
Total Assets | NA | 351 | 252 | 274 | 292 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 1 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 20 | 15 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 15 | 20 | 19 | 15 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 7 | 8 | 8 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 22 | 28 | 27 | 23 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 789 | 659 | 654 | 650 |
Retained Earnings | NA | -460 | -435 | -407 | -381 |
Other Equity | NA | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 329 | 224 | 247 | 269 |
Total Liabilities & Shareholder's Equity | NA | 351 | 252 | 274 | 292 |
Total Common Equity | 0 | 329 | 224 | 247 | 269 |
Shares Outstanding | 67.40 | 67.40 | 67.30 | 54.50 | 45.00 |
Book Value Per Share | 0.00 | 4.88 | 3.33 | 4.54 | 5.97 |